Introduction
============

Sepsis is a systemic inflammatory response syndrome caused by infection, which may lead to multiple organ dysfunction. It is the leading cause of mortality in critically ill patients ([@b1-mmr-14-06-5467]). The inflammatory response is primarily mediated by white blood cells (WBCs), including neutrophils (Neu), lymphocytes (Lym), and monocytes (Mon) ([@b2-mmr-14-06-5467],[@b3-mmr-14-06-5467]). Previous studies have suggested that the inflammatory response may be regulated by histone methylation ([@b4-mmr-14-06-5467]--[@b9-mmr-14-06-5467]).

Histone methylation regulates transcription and chromatin dynamics, and has roles in pathogenic development and the maintenance of normal physiology ([@b10-mmr-14-06-5467],[@b11-mmr-14-06-5467]). Methylation occurs on lysine and arginine residues of histone proteins ([@b12-mmr-14-06-5467]). Each lysine may undergo three different states of methylation, with one (mono), two (di), or three (tri) potential methyl groups being covalently attached to the amine group of the lysine side chain, and arginine may be mono- or di-methylated symmetrically or asymmetrically ([@b13-mmr-14-06-5467],[@b14-mmr-14-06-5467]). Histone methylation may repress or activate transcription, depending on the specific residues and modification states. Histone 3 lysine 9 (H3K9), H3K27 and H4K20 methylation are associated with transcriptional repression, whereas methylation of H3K4, H3K36 and H3K79 are associated with transcriptional activation ([@b15-mmr-14-06-5467]--[@b17-mmr-14-06-5467]).

Histone methylation is a reversible process, catalyzed by two antagonistic groups of enzymes, histone methyltransferases (HMTs) and demethylases (HDMs), with the levels of each of these determining the biological outcome ([@b18-mmr-14-06-5467]--[@b21-mmr-14-06-5467]). Certain studies have revealed that the process of inflammation and infection in inflammatory cells is regulated by histone methylation, including H3K4, H3K9 and H3K27 methylation ([@b4-mmr-14-06-5467]--[@b9-mmr-14-06-5467],[@b22-mmr-14-06-5467]--[@b24-mmr-14-06-5467]). Specific HMTs or HDMs were revealed to link histone methylation to transcriptional genes of inflammation/infection, including nuclear factor κB (NF-κB), tumor necrosis factor-α and interleukin-6, when inflammatory cells, particularly Mon or macrophages, were investigated *in vitro* ([@b4-mmr-14-06-5467]--[@b9-mmr-14-06-5467],[@b22-mmr-14-06-5467]--[@b24-mmr-14-06-5467]). The majority of studies that have been performed examined H3K9 methylation, and H3K9 dimethylation (H3K9me2) is primarily associated with the inflammatory response ([@b4-mmr-14-06-5467]--[@b9-mmr-14-06-5467],[@b22-mmr-14-06-5467]--[@b24-mmr-14-06-5467]). However, the specific histone methylation alterations that occur in the peripheral WBCs of patients with critical illness and sepsis remain to be elucidated.

The present study hypothesized that histone methylation in peripheral WBCs from patients is important in sepsis occurrence and progression. The current study established and optimized an immunofluorescence staining method to investigate H3K9me2 alterations in WBCs from critically ill patients. The pilot data provided clinical evidence for the hypothesis of histone methylation in WBCs, and suggested that the characteristic changes of histone methylation are a potential diagnostic and prognostic biomarker for septic patienthowever, further evaluation in a larger cohort is required.

Materials and methods
=====================

### Study design

The present study was approved by the Research Ethics Board of Zhongshan Hospital, Fudan University (Shanghai, China). Written informed consent was obtained from all recruited patients. The majority of patients admitted to the surgical intensive care unit (ICU) of Zhongshan Hospital were suffering from postoperative trauma or esophageal cancer, and were frequently affected by sepsitherefore, these two groups of patients became the focus of the present study. To minimize individual differences, each group comprised a similar number of patients within the same age range. Only male patients were enrolled to avoid gender bias. A total of 43 patients (23 trauma and 20 esophageal canceage range, 40--75 years) were enrolled in the present study between October 2012 and December 2014. The enrolled patients were divided into four groups: i) Trauma, ii) trauma+sepsis, iii) cancer and iv) cancer+sepsis. Exclusion criteria were: Patients with trauma and cancer, endocrine disorders (including diabetes and hyperthyroidism), obesity \[body weight 20% greater than the ideal standard, which is equal to height (cm)-105\], or any other chronic organ impairments. None of the cases had infectious diseases for more than two weeks prior to the sample collection.

Traumatic insults resulted from road accidents, accidental traumas and falls. The pathological diagnosis of all enrolled esophageal cancer patients was squamous cell carcinoma, grade II--III. Sepsis patients (12 trauma; 11 postoperative esophageal cancer) were diagnosed according to the 2001 International Sepsis Definition Conference ([@b25-mmr-14-06-5467]). The clinical and biochemical parameters of the subjects were recorded, including number, age and gender, Acute Physiology and Chronic Health Evaluation II (APACHE II) score ([@b26-mmr-14-06-5467]), Sequential Organ Failure Assessment (SOFA) score ([@b27-mmr-14-06-5467]), microbiological findings, site of infection, length of ICU stay, mortality occurring in ICU, C-reactive protein (CRP), procalcitonin and predominant variables of routine blood tests.

### Sample collection and preparation

Blood samples were collected within the first 24 h following operations in nonseptic patients, and following diagnosis of sepsis in septic patients. The blood was obtained using an existing arterial or venous catheter and transferred into a sterile heparin anticoagulatant vacutainer. Healthy volunteers donated 5 ml blood samples via the elbow vein. The samples were processed within 2 h following collection.

Samples were centrifuged at 1,200 x *g* for 15 min at 4°C and the plasma supernatant was collected for storage. Red blood cell lysis buffer (3 ml; Beyotime Institute of Biotechnology, Haimen, China) was added, and the blood cell samples were mixed at room temperature for 10 min, centrifuged at 1,000 x *g* for 2 min at 4°C, and the supernatant discarded. WBC samples were washed with PBS buffer 2--3 times. 293T cells (human embryonic kidney cells, kindly granted by Prof. Charlie Degui Chen, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, China) were grown in Iscove\'s DMEM containing in 10% fetal calf serum medium for 48 h. An aliquot of WBCs and 293T cells in a ratio of 4:1 were mixed and resuspended in PBS. Following this, 10 µl of the mixed cell suspension (\~1×10^4^ cells) was dropped vertically onto a slide. Following drying of the slide, the cells were fixed in 4% paraformaldehyde for 10 min, and washed with PBS 2--3 times. Finally, the slides were stored at −80°C until measurement.

### Western blot analysis

Proteins from the prepared WBCs were extracted using SDS lysis buffer (Beyotime Institute of Biotechnology). To examine H3K9me2 levels in WBCs, a 10 µg extract of cell proteins from these cells was separated on a 15% SDS-PAGE gel. The proteins were transferred to a polyvinyl difluoride membrane in blocking reagent \[5% milk in Tris-buffered saline (TBST)\] at room temperature for 30 min. The membrane was washed with 1X TBST three times. A mouse histone H3K9me2-specific antibody (1:2,000; cat. no. ab1220; Abcam, Cambridge, MA, USA) was used for western blot analysis, and a rabbit histone H3 antibody (1:5,000; cat. no. ab1791; Abcam) served as a loading control. The primary antibodies were incubated with the membrane at room temperature for 90 min. The membrane was then washed with 1X TBST three times, and incubated with goat anti-mouse and goat anti-rabbit horseradish peroxidase-conjugated secondary antibodies (1:10,000; cat. nos. 115-035-003 and 111-035-045; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) at room temperature for 60 min. Enhanced chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was subsequently used to visualize the blot.

### Immunofluorescence staining

The stored leukocyte slides were defrosted at room temperature for 20 min. Following washing with PBS, the cells were permeabilized with cold PBS containing 0.2% Triton X-100 for 5 min. Subsequent to blocking in 1% bovine serum albumin (Roche Diagnostics, Basel, Switzerland) in PBS at room temperature for 30 min, the cells were incubated with a H3K9me2 antibody (1:800; cat. no. ab1220; Abcam) in a humidified chamber at 37°C for 60 min, then incubated with the Cy3-labeled goat anti-mouse IgG (1:1,000; cat. no. 115-165-146; Jackson ImmunoResearch Laboratories, Inc.) at room temperature for 60 min, and stained with DAPI, and mounted prior to viewing. Fields with appropriate cell density were selected and observed by fluorescence microscopy with the exposure time of 2 msec for H3K9me2 and 130 msec for DAPI. The total leukocyte cell counts in each patient sample were all \>100 in 5 different fields.

The fluorescence intensity of different cells on the slide was analyzed by Image-Pro Plus software version 6.0 (Media Cybernetics, Inc., Rockville, MD, USA). The software allowed the staining intensity and area of each cell to be presented in one table. The quantitative intensity of the three WBC types in each sample was calculated as the mean intensity of all observed cells. All data were analyzed by two independent investigators, and the intensity values quantified individually were averaged by calculation of the mean to obtain the final intensity. Microsoft Excel software 2007 (Microsoft Corporation, Redmond, WA, USA) was used to calculate the fluorescence intensity of different cells.

### Statistical analysis

The data were analyzed using the unpaired Student\'s t-test for comparison of two groups, and one way analysis of variance for data from all four groups followed by the Bonferroni post-hoc test. All analyses were performed using Stata software version 10.0MP (StataCorp LP, College Station, TX, USA). Data are presented as the mean ± standard deviation. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient characteristics

[Table I](#tI-mmr-14-06-5467){ref-type="table"} presents a comparison of characteristics between non-septic and septic trauma (n=23) and esophageal cancer (n=20) patients. Routine blood tests revealed a normal WBC count in patients in the trauma group; however, levels of Neu and Mon in the other three groups were elevated, along with a reduced percentage of Lym. It was demonstrated that there were significant differences in the percentages of increased Neu and decreased Lym between sepsis and non-sepsis trauma patients. Additionally, the level of CRP was elevated in sepsis compared with non-sepsis grouphowever, this was not the case for procalcitonin ([Table I](#tI-mmr-14-06-5467){ref-type="table"}).

### Western blot analysis

The present study conducted a western blot analysis of the total level of histone methylation in whole WBCs in sepsis and non-sepsis patients. Notably, H3 from each sample contained three bands, with the largest band corresponding to the intact H3 probed with histone H3K9me2 antibody (data not shown), suggesting that the two smaller bands were derived from cleavage of histone H3 following K9 residues in WBCs. H3 cleavage following residues A21 to K27 in mouse embryonic stem cells has been reported previously ([@b28-mmr-14-06-5467],[@b29-mmr-14-06-5467]), suggesting that the cleaved N-terminal fragments, including A1-A21, A1-A23 and A1-A27, containing the target K9 residue, escaped detection. The present study therefore failed to obtain the total level of histone H3K9me2 from whole WBCs by western blot analysis. The levels of histone methylation from specific types of leukocytes were not identified or compared.

### Immunofluorescence staining of WBCs

To examine the level of histone methylation in different WBCs, the present study used an immunofluorescence staining method. Considering the complex cell components, wide range of cell number, and short survival time *in vitro* of peripheral WBCs, the leukocytes were directly separated within 2 h following blood collection to obtain the maximum number of live cells. Various suspension solvents and fixed slides were used to analyze leukocytes, due to complications in fixing the suspended WBCs onto a glass slide, and the suspension, blood smear and drop methods were compared. It was concluded that use of fresh leukocyte samples, PBS for cell suspension and the drop method enabled optimal immunofluorescence staining of WBCs.

To control for the influence of different staining operations and compare the immunofluorescence between samples, 293T cells were co-stained alongside WBCs, and served as a reference. 293T cells have stable and homogeneous staining intensity ([Fig. 1A](#f1-mmr-14-06-5467){ref-type="fig"}), and contain nuclei with a shape distinct to the three primary types of WBCs, Neu, Lym and Mon. Neu has a lobulated or rod-shaped nucleus with loose chromatin; Lym has a round or oval nucleus with dense chromatin; and Mon is larger than Lym, and has a kidney- or horseshoe-shaped nucleus with loose chromatin. The nuclei of 293T cells are irregular, round and significantly larger than those of WBCs ([Fig. 1B](#f1-mmr-14-06-5467){ref-type="fig"}).

### Sepsis-induced alterations of H3K9me2 in WBCs from trauma and cancer patients

Immunostaining analysis detected different levels of histone H3K9me2 in the three types of WBCs from trauma patients. The staining intensity of Lym was stronger than that of Neu and Mon ([Fig. 2](#f2-mmr-14-06-5467){ref-type="fig"}). The levels of H3K9me2 were elevated in different WBCs from cancer patients, and demonstrated a similar level of intensity to that exhibited by 293T cells ([Fig. 3](#f3-mmr-14-06-5467){ref-type="fig"}). In the trauma + sepsis group, the levels of H3K9me2 in all of the three WBCs increased \~20%, this was particularly observed for Neu (P=0.0005) and Mon (P=0.0002; [Figs. 2](#f2-mmr-14-06-5467){ref-type="fig"} and [4](#f4-mmr-14-06-5467){ref-type="fig"}). Notably, the presence of sepsis significantly reduced the elevation of H3K9me2 in cancer patients by 20 to 40% ([Figs. 3](#f3-mmr-14-06-5467){ref-type="fig"} and [4](#f4-mmr-14-06-5467){ref-type="fig"}). The serum CRP values from trauma and cancer patients were elevated when sepsis was present; however, there was no statistical significance indicated in the cancer patients ([Fig. 4](#f4-mmr-14-06-5467){ref-type="fig"}).

### Differential H3K9me2 expression in WBCs

The intensity of H3K9me2 in WBCs between non-septic patients with different underlying diseases, trauma and cancer, was compared. An increase of histone methylation in cancer patients was demonstrated, in the absence or presence of sepsis. However, the elevated histone methylation in the three WBCs in cancer and septic trauma varied. The H3K9me2 levels of Lym and Mon cells in cancer patients were similar compared with trauma patients with sepsis, whereas the levels in Neu cells were greater ([Fig. 4](#f4-mmr-14-06-5467){ref-type="fig"}).

These results indicated that immunofluorescence staining may be used to compare histone methylation in different WBCs. Sepsis in trauma and cancer patients had opposing effects on histone methylation; sepsis increased H3K9me2 levels in trauma patients and decreased them in cancer.

### Diagnostic significance of H3K9me2 in WBCs for sepsis

Furthermore, the H3K9me2 levels were used as a diagnostic marker for sepsis using a receiver operating characteristic analysis ([Fig. 5](#f5-mmr-14-06-5467){ref-type="fig"}). The diagnostic significance was evaluated by the area under the curve (AUC). The AUC values of H3K9me2 in the three WBCs from trauma patients were 0.70--0.73; these were reduced compared with the 0.98 demonstrated by CRP, indicating a poor predictive value of H3K9me2 for the occurrence of sepsis in trauma patients. By contrast, in cancer patients, the AUC values of H3K9me2 in the three WBCs were 0.88 for Neu, 0.84 for Lym and 0.80 for Mon, all greater than the 0.67 demonstrated by CRP ([Fig. 5](#f5-mmr-14-06-5467){ref-type="fig"}). A cutoff of 93.79 in Neu yielded 100% sensitivity and 66% specificity, 97.15 in Lym demonstrated 90% sensitivity and 77% specificity, and 86.05 in Mon demonstrated 81% sensitivity and 66% specificity for the occurrence of sepsis in cancer patients. Considering the percentage of Neu of total WBCs, H3K9me2 in WBCs exhibited a unique diagnostic significance for the occurrence of sepsis in cancer patients compared with the commonly used indicator.

Discussion
==========

Previous studies have suggested that the inflammatory response in sepsis is regulated by histone methylation, including H3K4, H3K9 and H3K27 methylation ([@b4-mmr-14-06-5467],[@b9-mmr-14-06-5467]). However, clinical evidence is lacking. The present study verified that the levels of histone methylation of peripheral WBCs were altered in critically ill patients.

The present study established and optimized an immunofluorescence staining method for WBCs. Using this method, immunofluorescence intensity in different leukocytes was simultaneously determined, and the levels of histone methylation from different patient samples were compared, with co-stained 293T cells serving as a reference. The results of the present study indicated that this method is applicable to a wider range of cellular targets. The data suggested that sepsis increased the levels of H3K9me2 in all three types of WBCs from trauma patients. The gene-specific silencing methylation is a key feature of the endotoxin tolerant phenotype demonstrated in a THP-1 human Mon model of severe systemic inflammation (SSI) and in blood polymorphonuclear leukocytes of patients with SSI ([@b6-mmr-14-06-5467],[@b8-mmr-14-06-5467],[@b24-mmr-14-06-5467],[@b30-mmr-14-06-5467],[@b31-mmr-14-06-5467]). A previous study suggested that the NF-κB component RelB was induced by activation of endotoxin, whereas RelB induced the formation of heterochromatin via a direct effect on the histone H3K9 methyltransferase G9a, thereby inhibiting the expression of acute proinflammatory genes to generate epigenetic silencing in endotoxin tolerance ([@b6-mmr-14-06-5467]). Additionally, the study suggested that histone H3K9 methylation was elevated during SSI, which is consistent with the results from the present study in trauma patients with sepsis.

By contrast, the occurrence of sepsis significantly downregulated H3K9 methylation in the three WBC types from esophageal cancer patients, which was elevated in the cancer group by 20--40% compared with the trauma group. The current study compared the levels of H3K9me2 in WBCs from three healthy volunteers and trauma patients by immunostaining analyses, and no marked difference was observed. These results suggest that H3K9 methylation in WBCs of cancer patients was upregulated prior to sepsis, and differently regulated in sepsis compared with trauma patients. Further research is required to elucidate an underlying mechanism.

Sepsis induced opposing effects on histone methylation in trauma and cancer patients, suggesting that differences in primary diseases should be considered. Inflammation in sepsis may not be similar in different primary diseases, with particular differences occurring in acute vs. chronic, and benign vs. malignant cases. Additionally, the potential abnormality may alter the background of the inflammatory response. Although CRP is a marker that is commonly used to detect inflammation or infection ([@b25-mmr-14-06-5467]), the disordered inflammatory state associated with cancer existed prior to sepsis, reflected by the greater percentage of Neu and elevated CRP levels in the cancer group compared with the trauma group. Pre-existing inflammation reduced the predictive power of CRP for sepsis. By contrast, H3K9me2 levels in WBCs exhibited a unique diagnostic significance for sepsis in cancer patients.

The present study observed altered H3K9me2 levels in peripheral blood leukocytes from critically ill patients via immunofluorescence analysis, with the opposite effect induced by sepsis in trauma and cancer patients. Further studies on the differential effects of sepsis on histone methylation are currently being performed. The observation that the level of H3K9me2 is altered in sepsis is of interest, and other histone methylations, including H3K4, H3K27, H3K36, H3K79, H4K20 and arginine methylation, will be investigated in the future. It may be important to determine other potential causes of sepsis that have a similar effect on histone methylation. Establishing a unique profile of histone methylation in sepsis may enable the development of novel strategies to manage sepsis.

In conclusion, the present study analyzed histone methylation in peripheral WBCs via immunofluorescence. The H3K9me2 levels in peripheral WBCs from trauma and cancer patients were different. Altered histone methylation in trauma and cancer patients with sepsis exhibited opposite trends, and may represent a potential diagnostic and prognostic biomarker for septic patients.
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![Immunofluorescence staining of H3K9me2 in 293T cells and three types of WBCs. (A) Homogenous fluorescence staining and intensity of H3K9me2 in 293T cells; DAPI was used to stain the nuclei. The scatter plot indicates that 293T cells demonstrated homogeneous staining. (B) Different nuclear morphology of 293T and three types of WBCs, Neu, Lym and Mon allows distinction of the four cell types. H3K9me2, histone 3 lysine 9 dimethylation; WBCs, white blood cells; Neu, neutrophils; Lym, lymphocytes, Mon, monocytes.](MMR-14-06-5467-g00){#f1-mmr-14-06-5467}

![Immunofluorescence staining of H3K9me2 in WBCs from trauma patients. Peripheral WBCs samples were obtained from two patients, trauma and trauma+sepsis. For each sample, the average intensity of H3K9me2 in 293T cells was defined as 100, and the relative quantitative value of H3K9me2 in each leukocyte was calculated. The relative fluorescence abundance of H3K9me2 in counted Neu, Lym and Mon cells is presented as the mean ± standard deviation. H3K9me2, histone 3 lysine 9 dimethylation; WBCs, white blood cells; Neu, neutrophils; Lym, lymphocytes, Mon, monocytes.](MMR-14-06-5467-g01){#f2-mmr-14-06-5467}

![Immunofluorescence staining of H3K9me2 in WBCs from cancer patients. Peripheral WBCs samples were obtained from two patients, cancer and cancer+sepsis. For each sample, the average intensity of H3K9me2 in 293T cells was defined as 100, and the relative quantitative value of H3K9me2 in each leukocyte was calculated. The relative fluorescence abundance of H3K9me2 in counted Neu, Lym and Mon cells is presented as the mean ± standard deviation. H3K9me2, histone 3 lysine 9 dimethylation; WBCs, white blood cells; Neu, neutrophils; Lym, lymphocytes, Mon, monocytes.](MMR-14-06-5467-g02){#f3-mmr-14-06-5467}

![Association of H3K9me2 and CRP levels. H3K9me2 levels in (A and B) Neu, (C and D) Lym and (E and F) Mon, and (G and H) CRP levels in patients with trauma and cancer is presented according to APACHE II scores. The APACHE II scores of all septic patients from trauma and cancer groups were \>10, whereas the scores of all patients without sepsis were between 0 and 10. Sepsis in trauma and cancer patients had opposing effects on histone methylation; sepsis increased H3K9me2 levels in trauma patients and decreased them in cancer. \*\*P\<0.01. H3K9me2, histone 3 lysine 9 dimethylation; APACHE II, Acute Physiology and Chronic Health Evaluation II; CRP, C-reactive protein; Neu, neutrophils; Lym, lymphocytes; Mon, monocytes.](MMR-14-06-5467-g03){#f4-mmr-14-06-5467}

![Receiver operating characteristic AUC of H3K9me2 and CRP levels in trauma and cancer patients. The AUC values were calculated for H3K9me2 levels in (A and B) Neu, (C and D) Lym and (E and F) Mon, and (G and H) CRP levels in patients with trauma and cancer. H3K9me2 levels had a poor predictive value for the occurrence of sepsis in trauma patients, but is a possible diagnostic marker for the occurrence of sepsis in cancer patients. AUC, area under the curve; CI, 95% confidence interval; H3K9me2, histone 3 lysine 9 dimethylation; Neu, neutrophils; Lym, lymphocytes; Mon, monocytes; CRP, C-reactive protein.](MMR-14-06-5467-g04){#f5-mmr-14-06-5467}

###### 

Clinical and biochemical parameters of study subjects.

  Variable                            Trauma        Trauma+sepsis                                                   Cancer        Cancer+sepsis
  ----------------------------------- ------------- --------------------------------------------------------------- ------------- -------------------------------------------------------------
  Primary etiology                    Trauma        Esophageal squamous cell carcinoma                                            
  Number                              11            12                                                              9             11
  Gender                              Male                                                                                        
  Age (years)                         52.46±17.17   62.17±18.47                                                     56.11±7.29    62.55±9.34
  APACHE II score                     2.64±2.11     16.58±6.58^[b](#tfn2-mmr-14-06-5467){ref-type="table-fn"}^      3.56±1.24     15.27±7.07^[b](#tfn2-mmr-14-06-5467){ref-type="table-fn"}^
  SOFA score                          0.45±0.69     7.33±4.89^[b](#tfn2-mmr-14-06-5467){ref-type="table-fn"}^       1.33±0.87     8.36±5.90^[b](#tfn2-mmr-14-06-5467){ref-type="table-fn"}^
  Infection                                                                                                                       
    Gram-positive bacteria            NA            5                                                               NA            4
    Gram-negative bacteria            NA            3                                                               NA            6
  Site of infection                                                                                                               
    Pulmonary                         NA            8                                                               NA            8
    Abdominal                         NA            5                                                               NA            3
    Other                             NA            0                                                               NA            1
  Patients with organ insufficiency   0             6                                                               0             7
  Length of ICU stay (days)           1±0           21.33±14.25^[b](#tfn2-mmr-14-06-5467){ref-type="table-fn"}^     9.11±7.36     15.63±9.23
  Mortality occurring in ICU          0             4                                                               0             2
  WBC (×10^9^/l)                      7.31±2.03     12.27±4.67^[b](#tfn2-mmr-14-06-5467){ref-type="table-fn"}^      13.63±3.52    14.84±4.96
    Neu (%)                           62.75±7.15    87.27±5.27^[b](#tfn2-mmr-14-06-5467){ref-type="table-fn"}^      83.13±2.30    88.78±3.39^[b](#tfn2-mmr-14-06-5467){ref-type="table-fn"}^
    Lym (%)                           28.51±7.91    7.62±4.56^[b](#tfn2-mmr-14-06-5467){ref-type="table-fn"}^       7.49±3.59     5.82±1.87
    Mon (%)                           6.53±1.96     5.20±2.04                                                       7.91±1.08     4.63±2.18^[b](#tfn2-mmr-14-06-5467){ref-type="table-fn"}^
  Procalcitonin (µg/l)                0.23±0.04     0.17±0.07^[a](#tfn1-mmr-14-06-5467){ref-type="table-fn"}^       0.24±0.06     0.20±0.07
  C-reactive protein (mg/l)           9.75±21.23    154.07±109.64^[b](#tfn2-mmr-14-06-5467){ref-type="table-fn"}^   40.95±27.84   91.74±77.18^[a](#tfn1-mmr-14-06-5467){ref-type="table-fn"}^

P\<0.05

P\<0.01 vs. non-sepsis patients. Data are expressed as the mean ± standard deviation. NA, not applicable; APACHE II, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment; WBC, white blood cells; Neu, neutrophils; Lym, lymphocytes; Mon, monocytes.
